Owlstone Medical Limited

Owlstone Medical Limited

The Owlstone detector is a revolutionary dime-sized device that can be programmed to detect a wide range of chemical agents that may be present in extremely small quantities. Using leading-edge micro- and nano- fabrication techniques, Owlstone has created a complete chemical detection system that is one hundred times smaller and one thousand times cheaper than existing technologies.

Telephone: +44 (0)1223 428 200
Address: 127 Cambridge Science Park, Milton Road, Cambridge
Postcode: CB4 0GD
Country: United Kingdom
Website: http://www.owlstonemedical.com
Membership type:Corporate 21-50 (£500+VAT pa)

laww

Owlstone Medical’s Breath Biopsy® platform is creating a new industry category, based on the routine detection and analysis of volatile organic compound (VOC) biomarkers in breath, which has the potential to revolutionize healthcare. The award winning ReCIVA Breath Sampler is the first standardized breath collection device designed to capture the VOC biomarkers present in breath, which are then analyzed using Owlstone Medical’s Breath Biopsy services and products.

Owlstone Medical is developing breath tests for the early detection of lung and colorectal cancer. These are two of the most common cancer killers worldwide and represent multibillion dollar market opportunities. The company has an active clinical diagnostics/screening pipeline including the world’s largest breath-based clinical trials. The Breath Biopsy platform is also being deployed in the PAN cancer trial, a collaboration with Cancer Research UK studying the early detection of eight different cancer types in breath.

The company also sees a significant role for Breath Biopsy in precision medicine, where it can provide dynamic information about a patient’s disease activity and identify patients most likely to respond to a particular therapy. Breath Biopsy aims to ensure that the right therapy is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs.

Owlstone Medical’s Breath Biopsy clinical laboratory is a unique, revenue generating capability that allows pharmaceutical, clinical and academic partners worldwide to explore breath-based biomarkers to optimize their own precision medicine activities. The commercialization of Breath Biopsy precision medicine companion diagnostics through pharmaceutical partners is expected to provide Owlstone Medical with a significant royalty stream as breath-based precision medicine becomes a reality.

Owlstone Medical was spun out of Owlstone Inc. in 2016 to develop and commercialize medical applications of its proprietary microchip chemical sensing technology, Field Asymmetric Ion Mobility Spectrometry (FAIMS), which is sold in the military and industrial sectors globally. The company has raised a total of $38.5 million in equity financing, and is backed by technology investor Horizons Ventures, and Aviva, a leading healthcare insurer.

Owlstone Medical is headquartered in Cambridge, UK.

Owlstone Medical

Owlstone Medical

By detecting chemicals in breath and bodily fluids, Owlstone technology promises to revolutionize healthcare.

Owlstone Medical appoints Dr Andy Richards CBE to Board of Directors

Owlstone Medical Ltd, a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.

14 September 2018Read in full

Owlstone Medical appoints five leading experts to Scientific Advisory Board

Owlstone Medical appoints five leading experts to Scientific Advisory Board

Owlstone Medical (or the “Company”), a diagnostics company developing a breathalyzer for disease, has announced the expansion of its Scientific Advisory Board (SAB) with the appointment of five leading experts in a range of high value disciplines as the Company expands and drives towards its goal of saving 100,000 lives and saving healthcare providers $1.5 billion.

19 July 2018Read in full

Owlstone wins MacRobert Award

Owlstone's Breath Biopsy platform scoops UK's most prestigious innovation award

The Royal Academy of Engineering reveals Owlstone Medical, creators of the ReCIVA Breath Sampler, as the winners of the 2018 MacRobert Award.

28 June 2018Read in full

Owlstone Medical's ReCIVA Breath Sampler used in hospital

Owlstone Medical in the running for top UK innovation prize

Cambridge-based Owlstone Medical is a finalist in the running for the UK’s most prestigious innovation award, the Royal Academy of Engineering MacRobert Award, continuing a tradition of success for local technology companies.

4 June 2018Read in full

European Mediscience Awards 2018 banner

Owlstone Medical is shortlisted for European Mediscience Awards 2018

Owlstone Medical is excited to be shortlisted for The Emerging Star Award of the European Mediscience Awards 2018.

17 May 2018Read in full

Owlstone Medical provides breath biopsy services to AstraZeneca

Owlstone Medical provides breath biopsy services to AstraZeneca

Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced it has signed a service agreement with AstraZeneca plc, a global biopharmaceutical company. The collaboration will explore how breath can be used to identify novel biomarkers to help differentiate between disease phenotypes relevant for asthma and COPD.

9 April 2018Read in full

The 2.0 Breath Biopsy Discovery VOC Kit

Owlstone Medical launches Breath Biopsy Kits

Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced the launch of its Breath Biopsy® Kits, based on the company’s proprietary Breath Biopsy platform. The new product range allows academic, clinical and pharmaceutical researchers to quickly discover and validate breath-based biomarkers in early detection and precision medicine research activities.

28 March 2018Read in full

Owlstone Medical’s  ReCIVA® Breath Sampler

Owlstone Medical raises £11 million with Horizons Ventures and Aviva

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, announced today that it has raised $15 million (£11 million) to drive the global commercialization of its Breath Biopsy® platform. The funds will enable the company to bring its lung cancer Breath Biopsy test to market, deepen the early detection pipeline with ongoing trials across multiple cancers, and further grow its existing precision medicine services to the pharmaceutical industry.

6 March 2018Read in full

ReCIVA  Breath Biopsy platform

Owlstone Medical’s breath biopsy wins global IPF Catalyst Challenge

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, is one of the three winners of the global Idiopathic Pulmonary Fibrosis (IPF) Catalyst Challenge, sharing the $1million (£720,000 GBP) award, each receiving $333,333 (£240,000 GBP).

26 January 2018Read in full

Owlstone Medical selected as finalist in IPF Catalyst Challenge

Owlstone Medical selected as finalist in IPF Catalyst Challenge

Owlstone Medical have been chosen as finalists in a competition for $1 million of funding for life-changing research into Idiopathic Pulmonary Fibrosis (IPF).

11 January 2018Read in full

  1. 1
  2. 2
  3. 3
20/09/2018

Graduate Python Developer

Owlstone’s mission is to save 100,000 lives and save health care providers $1.5B. We are currently seeking a Graduate Python dev...

Location: Cambridge
Salary: Competitive
More Info
03/09/2018

Clinical Lab Assistant

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
03/09/2018

Research Assistant

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
28/08/2018

Assay Development Laboratory Technician

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
28/08/2018

Supply Chain Co-ordinator

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
20/08/2018

Clinical Site Coordinator

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
15/08/2018

Analytical Assay Development Manager

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
15/08/2018

Clinical Trials Administrator

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
15/08/2018

Project Coordinator

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
15/08/2018

Talent Acquisition Partner

Owlstone Medical’s mission is to save 100,000 lives and save health care providers $1.5B. With several major projects underway t...

Location: Cambridge
Salary: Competitive
More Info
  1. 1
  2. 2